Yarrow Bioscience, Inc. Common Stock
YARW
32 hedge funds and large institutions have $14.3M invested in Yarrow Bioscience, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
3% more funds holding
Funds holding: 31 → 32 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.1% less ownership
Funds ownership: 1.1% → 1% (-0.1%)
11% less capital invested
Capital invested by funds: $16.1M → $14.3M (-$1.78M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$44.6K |
| 2 |
BlackRock
New York
|
+$42.6K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$34.7K |
| 4 |
Barclays
London,
United Kingdom
|
+$190 |
| 5 |
PCM
Prelude Capital Management
New York
|
+$190 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$740K |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$270K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$90.2K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$79.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$47.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $3.38K | – | – | – |
|
|
MLA
27
MB, Levis & Associates
Center Valley,
Pennsylvania
| $1.96K | – | – | – |
|
|
CA
28
Centerpoint Advisors
Needham,
Massachusetts
| $1K | – | – | – |
|
29
Russell Investments Group
London,
United Kingdom
| $351 | – | – | – |
|
30
JP Morgan Chase
New York
| $332 | – | – | – |
|
|
31
Barclays
London,
United Kingdom
| $188 | +$190 | +2 | New |
|
32
Wells Fargo
San Francisco,
California
| $122 | – | – | – |
|
|
33
UBS Group
Zurich,
Switzerland
| $26 | -$47.5K | -501 | Closed |
|
|
ATPW
34
Ashton Thomas Private Wealth
Scottsdale,
Arizona
| – | -$37 | – | – |
|
YARW Hedge Fund Activity: Q3 2024 in Review
32 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2024, worth a combined $14.3M — down 11% from $16.1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new YARW positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $44.6K. The largest seller was Silverarc Capital Management, cutting an estimated $740K.
- 32 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2024, up from 31 in Q2 2024.
- Funds reported $14.3M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2024, down 11% quarter-over-quarter.
- 2 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2024 was Renaissance Technologies, an estimated $44.6K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2024 was Silverarc Capital Management, an estimated $740K sold.
Based on aggregated 13F filings for Q3 2024.